- Home
- TSHA vs TNGX Comparison
TSHA vs TNGX Comparison
Compare TSHA & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TSHA | TNGX |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TSHA | TNGX |
|---|---|---|
| Price | $4.46 | $17.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | $10.56 | ★ $18.63 |
| AVG Volume (30 Days) | 2.1M | ★ 3.4M |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.50 | 26.89 |
| EPS | ★ N/A | N/A |
| Revenue | $8,333,000.00 | ★ $62,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $13.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $1.13 | $1.04 |
| 52 Week High | $6.02 | $17.63 |
Technical Indicators
Market Signals| Indicator | TSHA | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | 73.45 |
| Support Level | $4.41 | $10.90 |
| Resistance Level | $5.16 | N/A |
| Average True Range (ATR) | 0.20 | 1.15 |
| MACD | -0.00 | 0.49 |
| Stochastic Oscillator | 20.13 | 90.41 |
Price Performance
Historical ComparisonAbout TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.